Compound: Gusperimus
SMILES: O=C(NCCCCNCCCN)C(O)NC(=O)CCCCCCNC(=N)N
InChIKey: IDINUJSAMVOPCM-UHFFFAOYSA-N
Synonyms: Gusperimus, 98629-43-7, 15-deoxyspergualin, UJ0ZJ76DO9, Heptanamide, 7-((aminoiminomethyl)amino)-N-(2-((4-((3-aminopropyl)amino)butyl)amino)-1-hydroxy-2-oxoethyl)-, DTXSID60861078, Heptanamide, 7-[(aminoiminomethyl)amino]-N-[2-[[4-[(3-aminopropyl)amino]butyl]amino]-1-hydroxy-2-oxoethyl]-, gusperimusum, RefChem:144798, DTXCID00197287, L04AA19, N-(((4-((3-aminopropyl)amino)butyl)carbamoyl)(hydroxy)methyl)-7-carbamimidamidoheptanamide, Gusperimus [INN], 104317-84-2, N-[2-[4-(3-aminopropylamino)butylamino]-1-hydroxy-2-oxoethyl]-7-(diaminomethylideneamino)heptanamide, Gusperimus (INN), N-(2-((4-((3-Aminopropyl)amino)butyl)amino)-1-hydroxy-2-oxoethyl)-7-guanidinoheptanamide, BMS 181173, (+/-)-Deoxyspergualin, NCGC00183869-01, (+/-)-15-Deoxyspergualin; (+/-)-Deoxyspergualin;, UNII-UJ0ZJ76DO9, 1-amino-19-guanidino-11-hydroxy-4,9,12-triazanonadecane-10,13-dione, GUSPERIMUS [MI], GUSPERIMUS [WHO-DD], SCHEMBL28026, SCHEMBL147676, CHEMBL406117, orb1697038, CHEBI:135609, (+/-)-15-DEOXYSPERGUALIN, AKOS040751975, DB12692, HY-13644, NCI60_003229, DB-040531, ()-15-Deoxyspergualin; ()-Deoxyspergualin;, D08032, Q10910504, N-[2-[4-(3-aminopropylamino)butylamino]-1-hydroxy-2-oxo-ethyl]-7-guanidino-heptanamide, N-[4-(3-aminopropyl)aminobutyl]-2-(7-guanidinoheptanamido)-2-hydroxyethanamide, (+/-)-N-(((4-((3-AMINOPROPYL)AMINO)BUTYL)CARBAMOYL)HYDROXYMETHYL)-7-GUANIDINOHEPTANAMIDE, 7-([Amino(imino)methyl]amino)-N-[2-((4-[(3-aminopropyl)amino]butyl)amino)-1-hydroxy-2-oxoethyl]heptanamide #, Heptanamide, 7-(aminoiminomethyl)amino-N-2-[4-(3-aminopropylamino-butyl)amino)]-1-hydroxy-2-oxoethyl-, N-[2-({4-[(3-Aminopropyl)amino]butyl}amino)-1-hydroxy-2-oxoethyl]-7-(carbamimidoylamino)heptanamide, N-[4-(3-Aminopropylamino)butylcarbamoyl-hydroxy-methyl]-7-(diaminomethylideneamino)heptanamide
Theoretical properties:
molecular_formula: C17H37N7O3
molecular_weight: 387.5 g/mol
exact_mass: 387.29578807 g/mol
formal_charge: 0
hydrogen_bond_donor_count: 7
hydrogen_bond_acceptor_count: 6
rotatable_bond_count: 17
heavy_atom_count: 27
topological_polar_surface_area: 181 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
Descriptions:
pubchem: Gusperimus is a N-acyl-amino acid.
chembl: GUSPERIMUS is a small molecule listed in the ChEMBL database and has reached clinical trial phase 3.0.
wikipedia: Gusperimus is an immunosuppressive drug. It is a derivative of the naturally occurring HSP70 inhibitor spergualin, and inhibits the interleukin-2-stimulated maturation of T cells to the S and G2/M phases and the polarization of the T cells into IFN-gamma-secreting Th1 effector T cells, resulting in the inhibition of growth of activated naive CD4 T cells.
Gusperimus was developed by Bristol-Myers Squibb. Currently, it is manufactured and sponsored for use as an orphan drug and for clinical studies by the Japanese company Euro Nippon Kayaku. The patent claim (see quotation) is that Gusperimus may be useful for a variety of hyperreactive inflammatory diseases such as autoimmune diseases. The drug is available in vials containing 100 mg each.
There is little information about the pharmacokinetic properties of gusperimus.